Zhai Xiaoya, Shi Jialin, He Yiping, Xu Yangmiao, Cai Xiaona
Department of Cardiology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.
School of Medicine, ShaoXing University, Shaoxing, Zhejiang, China.
Anatol J Cardiol. 2025 Aug 27;29(9):457-71. doi: 10.14744/AnatolJCardiol.2025.5097.
Atrial fibrillation (AF) is the most common type of heart arrhythmia. Hypertension (HTN) is known as the most common risk factor for AF. The purpose of this study is to compare clinical results of combined renal denervation (RDN) and pulmonary vein isolation (PVI) in AF patients with HTN.
A systematic search was conducted on patients with AF and HTN, comparing the differences between RDN and PVI with PVI alone. The risk ratio (RR) of categorical variables and the mean difference of continuous variables with a 95% confidence interval were applied.
This meta-analysis included 10 studies with a total of 875 patients. 420 patients were in the RDN + PVI group (48%) while 455 (52%) were in the PVI group. 694 patients had paroxysmal AF (79.3%) and 181 patients had persistent AF (20.7%). At 12 months follow-up, the treatment of RDN + PVI reduced the overall risk of AF recurrence in HTN patients (RR = 0.64, P < .001, 95% confidence interval [CI]: 0.55-0.75). When pooled, the patients in the RDN + PVI group showed significant mean reductions in systolic blood pressure (BP) (-13.39 mm Hg, P < .001) and diastolic BP (-7.14 mm Hg, P < .001) compared to PVI alone. Meanwhile, PVI + RDN significantly increased the estimated glomerular filtration rate (+8.72 mL/min/1.73 m2, P < .001) compared with PVI alone. There was no significant difference in complications between the 2 groups.
Combined therapy of RDN + PVI seems more efficacious and superior to PVI alone in treating AF. Further and larger trials are needed to fully prove these outcomes.
心房颤动(AF)是最常见的心律失常类型。高血压(HTN)是已知的AF最常见危险因素。本研究的目的是比较在合并高血压的AF患者中,肾动脉去神经支配(RDN)与肺静脉隔离(PVI)联合治疗的临床效果。
对AF和HTN患者进行系统检索,比较RDN与PVI联合治疗和单纯PVI治疗之间的差异。应用分类变量的风险比(RR)和连续变量的平均差及95%置信区间。
该荟萃分析纳入10项研究,共875例患者。420例患者在RDN + PVI组(48%),而455例(52%)在PVI组。694例患者为阵发性AF(79.3%),181例患者为持续性AF(20.7%)。在12个月随访时,RDN + PVI治疗降低了高血压患者AF复发的总体风险(RR = 0.64,P <.001,95%置信区间[CI]:0.55 - 0.75)。汇总分析时,与单纯PVI相比,RDN + PVI组患者的收缩压(BP)显著降低(-13.39 mmHg,P <.001),舒张压(-7.14 mmHg,P <.001)。同时,与单纯PVI相比,PVI + RDN显著提高了估计肾小球滤过率(+8.72 mL/min/1.73 m2,P <.001)。两组并发症无显著差异。
RDN + PVI联合治疗在治疗AF方面似乎比单纯PVI更有效且更具优势。需要进一步开展更大规模的试验来充分证实这些结果。